← Back to Search

Topical Agent

PF-07295324 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 and day 10
Awards & highlights
No Placebo-Only Group

Summary

This trial tests two skin creams on healthy adults to see if they are safe and how they are absorbed by the body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 and day 10
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 and day 10 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
AEs following multiple ascending dose (MAD)
Incidence and severity of application site Adverse Events (AEs) as assessed by Draize score.
Incidence of laboratory abnormalities
+1 more
Secondary study objectives
Apparent Oral Clearance (CL/F)
Apparent Volume of Distribution (Vz/F)
Area Under the Curve From Time Zero to End of Dosing Interval (AUCτau)
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: PF-07295324Experimental Treatment1 Intervention
Ointment
Group II: PF-07259955Experimental Treatment1 Intervention
Cream
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07295324
2022
Completed Phase 1
~30
PF-07259955
2022
Completed Phase 1
~30

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,649 Previous Clinical Trials
17,744,352 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,536 Previous Clinical Trials
14,915,540 Total Patients Enrolled
~6 spots leftby Nov 2025